CINtec PLUS Cytology test more effective than HC2 HPV test in identifying women with precancerous lesions
Ventana Medical Systems, Inc., a member of the Roche Group, today announced the publication of further results from the Primary ASC-US LSIL Marker Study (PALMS) in this month's issue of Cancer Cytopathology. The PALMS study, which enrolled more than 27,000 women from five European countries, was designed to evaluate the diagnostic performance of the CINtec PLUS Cytology test in detecting pre-cancerous cervical disease compared to HPV testing and more traditional screening methods like Pap cytology.